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Johannes Möller *, Tanja Hernández Rodŕıguez, Jan Müller, Lukas Arndt, Kim B. Kuchemüller,
Björn Frahm, Regine Eibl, Dieter Eibl, Ralf Pörtner
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Abstract6
Knowledge-driven design and reliable scale-up of biopharmaceutical pro-7
duction processes with mammalian cells are key in Quality by Design. In8
this study, a model-based workflow is described to computationally evaluate9
the bioprocess dynamics during process transfer and scale-up. This enables10
a knowledge-driven evaluation of the process and thus provides a decision-11
making tool for accelerated bioprocess development. First, a mathematical12
process model describes the bioprocess dynamics of different state variables13
(e.g. cell density, titer). Second, the model parameter probability distribu-14
tions are determined at different scales based on measurement errors and the15
process variability is predicted. Third, the determined parameter distribu-16
tions are statistically compared to evaluate if the process dynamics have been17
changed and further actions are recommended. This workflow was successfully18
tested for the scale-up of an antibody-producing CHO fed-batch process from19
development scale (30 ml) to process implementation (250 ml) and scale-up20
to 2 l laboratory and 50 l pilot scale.21
Keywords: Monte Carlo methods, Process modeling, Parameter distributions,22
Process validation, model-assisted Design of Experiments, Quality by Design23
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1 Introduction25
Reliable design and scale-up of biopharmaceutical production processes with mam-26
malian cell culture are essential in Quality by Design (QbD). First, a stable and27
productive process needs to be identified during process development after clone se-28
lection. This includes screening studies of medium components (Torkashvand et al.,29
2015; Rouiller et al., 2014) and the definition of a stable and effective process strat-30
egy (e.g. fed-batch) (Wurm, 2004; Gmeiner et al., 2015). Mathematical process31
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modeling is an efficient tool during this step because it includes the most impor-32
tant mechanistics of the biological system. Moreover, mathematical process models33
describe the interactions between process parameters and key performance indica-34
tors, which is a substantial part of QbD (Guideline et al., 2009; Herwig et al., 2015;35
Carrondo et al., 2012). More process knowledge is incorporated during modeling36
if uncertainty quantification is performed, i.e. determining the effect of input un-37
certainties (e.g. experimental variations) on model outcomes (Sin et al., 2009; Liu38
and Gunawan, 2017; Anane et al., 2019). Uncertainty-based modeling techniques39
have been widely used in chemical systems or systems biology (Möller et al., 2018,40
2019a), but not often in bioprocess simulation studies (Rodŕıguez et al., 2019).41
Second, the bioprocess including its process strategy needs to be scaled up, for which42
mostly data-driven approaches are used. This is conventionally done by keeping a43
hydrodynamic state constant, e.g. volumetric power input (P/VL) (Klöckner et al.,44
2012; Catapano et al., 2009), mixing time (Varley and Birch, 1999; Rosseburg et al.,45
2018), impeller tip speed (Ju and Chase, 1992; Alsayyari et al., 2018) or the volumet-46
ric mass transfer coefficient kLa (Xing et al., 2009; Nienow et al., 1996). Therefore,47
it is recommended to hydrodynamically characterize the bioreactors at each scale48
(recommendation see (Meusel et al., 2016)). Additionally, computational fluid dy-49
namics (CFD) has gained rising importance to obtain an improved understanding of50
the bioreactor hydrodynamics from small to large scale (Sharma et al., 2011; Werner51
et al., 2014; Kaiser et al., 2011; Nienow et al., 2013). However, the cellular behavior52
including metabolism and productivity could vary at different bioreactor scales due53
to e.g. differences in the hydrodynamic stress (Sieck et al., 2013; Neunstoecklin54
et al., 2015) or pH gradients (Ivarsson et al., 2015; Brunner et al., 2017). So far,55
purely data-based scale-up procedures do not consider the dynamics of the biopro-56
cess. Therefore, it is not ensured that the previously developed process strategy is57
scaled up sufficiently and that the process dynamics stay constant during scale-up.58
In this study, a workflow is introduced to computationally evaluate the process dy-59
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namics, described by a mathematical process model, at different bioreactor scales.60
This concept is based on the determination and statistical comparison of the proba-61
bility distributions of model parameters under consideration of experimental uncer-62
tainty. Thus, the model incorporates the current process understanding and enables63
a knowledge-driven decision making. The workflow is tested for the model-based64
evaluation of an antibody-producing CHO fed-batch cultivation process during the65
scale-up from process development scale (30 ml shake flask) to process implementa-66
tion at 250 ml and 2 l bioreactor scale. Finally, it is shown how the mathematical67
model is used to determine the operating range during the process transfer to a 50 l68
pilot scale bioreactor.69
1.1 Proposed model uncertainty-based workflow70
As can be seen at the beginning of Figure 1, experimental data sets at two different71
bioprocess scales are used as input (exemplary Scale A and Scale B), e.g. process72
development and process implementation scale (typically using different bioreactor73
systems). Please notice that this study does not focus on how the scale-up needs to74
be performed hydrodynamically. The aim was to develop a method to statistically75
evaluate if the process dynamics are comparable at both scales and if the targeted76
process optimum (i.e. process strategy) is still met.77
[Figure 1 about here.]78
The basis of the introduced concept is the quantification of model-parametric un-79
certainties under consideration of experimental uncertainty due to variability in80
measurements (box 1). The model parameters are estimated multiple times (Monte-81
Carlo sampling) for each investigated scale under the assumption of normally dis-82
tributed measurement errors for each observable to determine the parameter distri-83
butions. Then, the parameter distributions and the prediction quantiles are used to84
visualize the process variability based on the model parameter distributions (box 2).85
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In the next step (box 3), a statistical comparison of the parameter distributions is86
performed to evaluate if there are statistically significant differences between both87
scales. The same process dynamics and targeted process strategy could be ensured88
if no changes in the parameter distributions are identified. Otherwise, if the param-89
eters differ significantly, a validation of the process strategy is recommended (box 4,90
e.g. adjusting the feed composition). In this validation step, a previously introduced91
model-assisted Design of Experiments (mDoE) concept is used to re-adjust the pro-92
cess strategy with a reduced number of experiments (Möller et al., 2019b). Based on93
this, it is recommended to enter further process development/process optimization94
studies or to proceed with scale-up if the validation was successful. This reflects a95
knowledge-driven methodology in QbD and can be repeated for every scale-up step.96
2 Materials and Methods97
The process design scaled up in this study was generated at the Institute of Bio-98
process and Biosystems Engineering (Hamburg University of Technology-TUHH)99
and was then transferred to the Institute of Chemistry and Biotechnology (Zurich100
University of Applied Sciences-ZHAW) for scale-up. Therefore, slightly different101
cultivation protocols and analytical methods were applied during this study.102
2.1 Mathematical process model103
An unstructured and non-segregated mechanistic process model was used in this104
study to compare the dynamics of the investigated process at different scales. It105
was previously described in (Kern et al., 2016; Möller et al., 2019b). In brief, the106
model describes cell growth (Xt - total cell density, Xd - dead cell density, Xv -107
viable cell density) and cell death based on the concentrations of glucose (cGlc) and108
glutamine (cGln) and growth inhibition due to ammonium (cAmm). The progression109
of the glucose and glutamine concentrations are coupled to the formation of lactate110
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(cLac) and ammonium. The antibody (cAb) is modeled to be expressed constantly111
per cell. The model also includes the mass balances involved in the bolus fed-112
batch processes and the model equations are summarized in Supplementary Table 1113
for easier reference. All computational methods in this study were performed in114
MATLAB 2018a.115
2.2 Monte Carlo-based uncertainty quantification116
The core of the proposed method is the quantification of parametric model uncertain-117
ties and comparison of these probability distributions at different scales based on the118
experimental variability. Therefore, a normally distributed observational error of 5%119
relative standard deviation was assumed based on the typical measurement standard120
deviations of analytical methods in bioprocess evaluation (i.e. expert knowledge)121
(Wechselberger et al., 2013). In order to propagate this input uncertainty onto para-122
metric uncertainty, Monte Carlo samples were generated (observational error) and123
the model parameters were adapted using the Nelder-Mead optimization algorithm124
(Nelder and Mead, 1965; Singer and Singer, 2004). The objective/cost function125
was the weighted sum of squared residuals between the simulations (ysim,j(ti)) in126
comparison to the experimental data (yj(ti)) over all time points t1, ..., tN and all127
variables y1, ..., yM , normalized on the assumed measurement variance σj, which is128
defined as 5% of the maximum value of a data set (yj,max) for the j-th observable129
(i.e. σj = 0.05 · dj,max). The experimental data was sampled 1000 times and the130
model parameters were adapted for each sampling. The initial values are shown131
in Supplementary Table 2 and were the same in all compared scales. Xv and cAb132
were weighted with 100 and cAmm with 10. 4 out of 29 experiments were randomly133
sampled and the parameters were estimated for the experiments performed during134
the identification of the feeding strategy. In the other scales, all experimental data135
was used.136
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2.3 Statistical comparison of probability distributions137
The means of the determined model parameter distributions were statistically com-138
pared for two different bioreactor scales (see Figure 1, Scale A and Scale B, re-139
spectively) to identify changes in the process dynamics. Therefore, the relative140
95%-confidence interval (CI) for the difference in means was calculated. For two141
samples x1, ..., xn and y1, ..., ym (representing the distribution of one model param-142
eter at two different scales) the means x and y and the sample variances σ2x and143
σ2y were computed. According to the central limit theorem, the difference in means144
d = x−y of samples with large sample sizes follows a normal distribution, character-145
ized by N (x− y, σ2x/n+ σ2y/m). Then, the 95%-confidence interval of the difference146
in means were calculated:147
[
x− y − 1.96
√
σ2x/n+ σ
2
y/m, x− y + 1.96
√
σ2x/n+ σ
2
y/m
]
. (1)
In order to test for a statistically significant difference in means of at least 5%, a148
model parameter was assigned to be significantly different, if the corresponding CI149
contains 5%.150
2.4 Monte Carlo-based uncertainty bands151
Quantification and graphical representation of the propagated uncertainty in the152
process dynamics was performed with Monte Carlo methods, thus repeated simula-153
tions of the process with the 1000 previously determined parameter sets were carried154
out (2.2). The mean and the 10% and 90% quantiles of simulation were calculated155
with the function ”prctile” (MATLAB 2018a, exact mode) (Langford, 2006).156
2.5 Validation of process strategy157
A validation of the process strategy (box 4 in Fig. 1) is recommended if the model158
parameter distributions (2.2) are significantly different. This is motivated based on159
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the identified change of the bioprocess dynamics and is seen to support knowledge-160
driven decision making. Commonly, Design of Experiments (DoE) methods are161
applied to develop and validate the process strategy on different scales (e.g. during162
late stage process optimization) (Legmann et al., 2009; Brunner et al., 2017; Abt163
et al., 2018). (Möller et al., 2019b) proposed a model-assisted DoE method (mDoE)164
which combines mathematical process modeling with statistical tools to significantly165
reduce the number of experiments. This concept was adapted in this study to166
validate the process strategy. In brief, a DoE is planned using suitable software (here:167
DesignExpert 11, Statcon, USA) and the recommended experiments are simulated168
instead of being experimentally performed. The responses (e.g. titer) are included169
into the DoE evaluation with a quadratic response surface model (all hierarchical,170
αout < 0.1, adjusted R-squared criteria). Please see (Möller et al., 2019b) for more171
information about the general concept of mDoE.172
2.6 Identifiability analysis173
Monte Carlo simulations were used to evaluate whether the parameters can be reli-174
ably estimated with acceptable accuracy (Miao et al., 2011). Therefore, the prop-175
agation of the input uncertainties onto the uncertainty in model simulations were176
quantified. For each model parameter, the whole sample of adapted values (rep-177
resenting the probability distribution of this model parameter) was considered and178
the average relative estimation deviation was computed. After adapting the model179
to each of the N simulated data sets to obtain parameter estimates θ̂(k) for the180
k-th parameter, the sample mean of the k-th parameter θ
(k)
and the corresponding181
relative average deviation (RAD(θ(k))) was computed according to:182
RAD(θ(k)) = 100% · 1
N
N∑
i=1
|θ̂(k)i − θ
(k)
i |
|θ(k)i |
. (2)
A low RAD-value reflects a practical identifiability of the corresponding parameter183
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component (Miao et al., 2011; Anane et al., 2019). Nevertheless, no general fix184
threshold can be applied since the relative average deviation also depends on the185
measurement error. Therefore, the assessment relies on the underlying problem and186
expert. In our study, we considered the histograms of the obtained distribution-187
s/samples in order to define an adequate threshold below 20%.188
2.7 Sensitivity analysis of model structure189
The sensitivity of the model simulations based on the input parameter uncertainties190
was quantified using the change of the maximum viable cell density Xv,max. One191
model parameter θ(k) at a time was varied within its previously derived probability192
distribution (2.2), meanwhile keeping all other parameters constant and computing193
the resulting target output values (Loucks and Van Beek, 2017). The resulting194
probability distribution of the target variable was compared to the input probability195
distribution. This was realized by comparing the relative width of the 80%-intervals196
of both distributions, ∆θi and ∆Xv,max , with a quantitative sensitivity coefficient S:197
S =
∆Xv,max
∆θ(k)
. (3)
A parameter was significantly sensitive if S was above 5%.198
2.8 Engineering parameters during scale-up199
All investigated bioreactors were hydrodynamically characterized (Meusel et al.,200
2016; Kaiser et al., 2015) and engineering parameters were compared with respect201
to cell growth, metabolism, and product titer during scale-up and in scale-down202
models (not part of this work). Based on this, a specific power input of 19 W m−3203
was identified as the scale-up criterion, which was kept constant in this study at all204
investigated stirred bioreactor scales.205
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2.9 Cultivations206
All cultivations considered in this study were performed in single-use bioreactors207
and are summarized in Table 1, including their scale and cultivation system.208
[Table 1 about here.]209
2.10 Cell line and preculture210
Suspension growing CHO DP-12 cells, producing an Interleukin-8 (IgG-1) anti-211
body (clone #1934, ATCC CRL-12445), were cultivated in this study (provided212
by Prof. Dr. T. Noll, Bielefeld University, Germany). TC-42 medium (chemi-213
cally defined, animal component-free, Xell AG, Germany) was supplemented with214
6 mmol l−1glutamine, 0.1 mg · l−1 LONG R3 IGF-1, and 200 nmol l−1 Methotrex-215
ate (all Sigma-Aldrich). Precultures were performed in shaken single-use Erlenmeyer216
baffled flasks (40 ml working volume, Corning, USA). The incubators (LT-XC, Kuh-217
ner, Switzerland or Multitron cell, Infors HT, Switzerland) were controlled at 37 ◦C,218
5 % CO2 (LT-X) or 7.5 % CO2 (Multitron cell) and 85 % humidity with shak-219
ing speeds between 120 rpm (25 mm shaking diameter, Multitron cell) - 200 rpm220
(12.5 mm shaking diameter, LT-XC). The cells were expanded in shake flasks and221
no maintenance culture was used.222
2.10.1 Identification of feeding strategy223
The fed-batch strategy was designed in a previous study (see (Möller et al., 2019b))224
using mDoE to reduce the boundary values of an experimental design. There, the225
proposed method (mDoE) was tested and compared to the fully implemented exper-226
imental design with 29 experiments, which were performed in shake flasks (30 ml,227
2 blocks, 14 and 15 parallel experiments). In brief, the incubator (LT-XC, Kuhner)228
was the same as explained above (2.10) with an increased shaking speed (220 rpm).229
The feeding design was varied (feed: Chomacs basic feed, Xell AG) with regard to230
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the start times of bolus feeding (48 h, 72 h, 96 h), the feeding rate (3 ml d−1 -231
6 ml d−1) and concentrations of glucose (111 mmol l−1 - 222 mmol l−1) and glu-232
tamine (9 mmol l−1 - 38 mmol l−1). In this study, these data was used to estimate233
the model parameter distributions of the process development scale (30 ml shake234
flasks). Please see (Möller et al., 2019b) for more information.235
2.10.2 Process implementation and process validation at 250 ml scale236
The formerly identified fed-batch strategy was transferred to the Ambr 250 mod-237
ular system (Sartorius Stedim Biotech). 0.3 · 106 cells ml−1 were inoculated and238
the starting volume was 200 ml. Following feeding (feed as above) steps referring239
to the starting volume were performed: 48 h: 2.55 %; 72 h: 5.1 %; 96 h, 120 h,240
144 h: 10.625 %. Temperature was set to 37◦C and headspace aeration to 0.1 vvm.241
Dissolved oxygen was controlled at a minimum of 40 % (submerse sparging with242
oxygen if needed). pH was controlled at 7.2 with CO2 submerse sparging. Stir-243
rer speed was adapted to the culture volume, keeping the specific power input of244
19 W m−3 constant. During the process validation, the starting volume of the biore-245
actor (previously 200 ml) was altered to 230 ml (F=0.5) and 170 ml (F=1.5) due to246
the change in feeding volumes.247
2.10.3 Process scale-up (2 l scale)248
Cells were expanded using 125-500 ml single-use shake flasks (Corning) with 40-249
160 ml working volume. Starting volume was 1440 ml (UniVessel SU 2L bioreactor,250
Sartorius Stedim Biotech). The feeding steps were performed based on the starting251
volume as described above (2.10.2). All process parameters were the same as in252
Ambr experiments.253
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2.10.4 Pilot scale (50 l)254
Cells were expanded using 125-500 ml single-use shake flasks (Corning) with 40-255
160 ml working volume and a wave-mixed bag with 5 l working volume (Cultibag RM256
10 l basic, Sartorius Stedim Biotech). For the pilot scale cultivation, the BIOSTAT257
STR50 (Sartorius Stedim Biotech) was used with 34 l starting volume. Feeding was258
performed as previously described (2.10.2).259
2.11 Analytical methods260
2.11.1 Identification of feeding strategy261
For the identification of the feeding strategy (TUHH), the cell concentration was262
determined with the Z2 particle counter (Z2, Beckman Coulter, USA) and the vi-263
ability was measured using the DAPI (4,6-diamidin-2-phenylindol, Sigma-Aldirch)264
method. Glucose, glutamine, and lactate concentrations were measured with the265
biochemistry analyzer YSI 2900D (Yellow Springs Instruments, USA). The con-266
centration of ammonium was enzymatically determined with a test kit (AK00091,267
nzytech, Portugal). Antibody titer was quantified using high performance liquid268
chromatographic system (HPLC, Knauer Smartline, Germany) with a Poros-A col-269
umn (Thermo Fisher Scientific, USA; 0.1 ml) according to the manufacturers pro-270
tocols. Rituximab (Roche, Switzerland) was used as standard and samples were271
measured in duplicates.272
2.11.2 Process implementation, re-adjustment, scale-up and pilot scale273
For the experiments in stirred bioreactors (at ZHAW), living cell density and vi-274
ability were measured with the NucleoCounter NC-200 (ChemoMe-tec, Denmark).275
Glucose, glutamine, lactate, and ammonium were analyzed with the BioProfile 100276
Plus (NovaBiomedical, Germany). The antibody was quantified with the Cedex Bio277
(Roche, Switzerland).278
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3 Results and Discussion279
This study aims to introduce a model uncertainty-based workflow (see Fig. 1) for280
the evaluation of the bioprocess dynamics at different scales using model paramet-281
ric uncertainty quantification and statistical tests. In the beginning, the feeding282
strategy and the mathematical model of the process development data (shake flask283
cultures, 30 ml-50 ml) is discussed. Then, the feeding strategy was transferred to284
250 ml stirred bioreactors and three cultivations were performed. The model param-285
eter distributions were determined and compared between the process development286
(shake flask) and 250 ml bioreactor scale. Furthermore, scale-up from 250 ml bio-287
processes to 2 l was statistically validated and the obtained parameter distributions288
(250 ml and 2 l, respectively) were used to predict the variability of a 50 l pilot scale289
run.290
3.1 Process development (30 ml): Identification of fed-batch291
strategy292
As was described in (Möller et al., 2019b), the identified optimal process strategy in293
shake flask cultivations was: start of bolus feeding after 96 h, glucose concentration294
in feed = 222 mmol l−1, glutamine concentration in feed = 9 mmol l−1 and a feeding295
rate of 10% v/v (3 ml d−1). Here, it was aimed to transfer this process strategy from296
shake flasks to stirred bioreactors and scale the process up to pilot scale. Therefore,297
it was evaluated that the process dynamics remain constant during scale-up.298
3.1.1 Estimation of model parameters299
668 data points (29 fed-batch cultivations, see 2.10.1) were used as data for the300
determination of the model parameter distributions (2.2), which are summarized301
in the Supplementary Figures 1 - 16. All cultivations were additionally simulated302
with the mean of the individual parameter distribution and the comparison of the303
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simulated to the measured data is shown in Figure 2.304
[Figure 2 about here.]305
The viable (Fig. 2, A), dead (Fig. 2, B) and total cell density (Fig. 2, C) were306
sufficiently reflected by the average parameter values. The antibody concentration307
(Fig. 2, D) was simulated with an R2 = 0.56 and NRMSD = 0.19 and reflects308
the general relationships, but the maximal antibody concentration was partly over-309
predicted after 144 h. The modeling of the product formation is widely discussed310
in literature (Zeng et al., 1998; Pörtner and Schäfer, 1996; Ben Yahia et al., 2015;311
Möller et al., 2018) and the here modeled constant cell-specific productivity is a312
rather simple approach, but sufficient for process optimization. Glucose was simu-313
lated with high accuracy in all cultivations (R2=0.75, NRMSD=0.08), but lactate314
concentration (Fig. 2, F) was only simulated with high accuracy for the formation315
of lactate during the first 144 h (R2 = 0.56, indicated by *). After that, no further316
increase in lactate was measured. This is a typical effect in pH-uncontrolled shake317
flask cultivations (Zhou et al., 2011) and no impact of lactate on cell growth was318
identified previously for this cell line (Möller et al., 2018, 2019b). The concentration319
of glutamine is predicted well if considering only the first 96 h of cultivation (Fig. 2,320
G; indicated by **). However, it differs from the simulation towards the end of the321
cultivation, presumably due to changing pH and ammonium concentrations. Cell322
growth is highly dependent on the glutamine availability and the range of fed glu-323
tamine is rather high (9 mmol l−1 - 38 mmol l−1). This leads to a negative R2, but324
an overall acceptable simulation. The concentration of ammonium was predicted325
with an R2 = 0.52.326
Overall, the average model simulations reflect the culture dynamics acceptably for327
the high amount of data and investigated process strategies in shake flask cultures.328
Furthermore, the process knowledge is increased throughout the mathematical mod-329
eling (Carrondo et al., 2012). The model parameter distributions reflect the para-330
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metric uncertainty and the process variability, which are further used to validate331
the process dynamics during scale-up.332
3.1.2 Identifiability analysis333
Practical identifiability of each parameter was analyzed based on the obtained pa-334
rameter distribution, interpreting the corresponding histograms as well as the RAD335
(Miao et al., 2011). Therefore, the histograms of all parameters (see Supplementary336
Figure 17-20) show high frequencies in the center and low frequencies on the tails337
on both sides, for which practical identifiability was concluded. This is confirmed338
by the resulting RAD values, which range from 5% - 14%.339
3.1.3 Sensitivity analysis340
A sensitivity analysis was performed to reduce the number of adapted and compared341
parameters to the sensitive ones only (see 2.7). The parameters shown in Table 2342
were identified to be sensitive:343
[Table 2 about here.]344
µmax was identified to be the most sensitive parameter, which is typical in Monod-345
type models as the main parameter describing Xv, which is linked to all differential346
equations (Supplementary Table 1). Moreover, the parameters associated with the347
glutamine metabolism (qGln,max, kGln) are sensitive because the glutamine concen-348
tration, as a main substrate (besides glucose), is also directly linked to cell growth.349
The inhibitory effect of ammonium is also linked to Xv and the ammonium-related350
model parameters YAmm,Gln and kAmm are sensitive. The sensitivity of glucose-related351
model parameters is rather low (kS,Glc). qAb describes the cell-specific antibody pro-352
duction and is sensitive regarding the product formation and was therefore included.353
Only these parameters were re-adjusted in the following evaluation of the scale-up354
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procedure and for the non-sensitive parameters, the previously determined average355
values were used (Supplementary Table 3).356
3.2 Transfer from process development to process imple-357
mentation358
The cell line, the cultivation protocols and the process strategy were transferred to359
a different research institute (TUHH to ZHAW), comparable to a tech transfer from360
research and development to process implementation and scale-up. In the beginning,361
the process strategy was scaled up to a stirred bioreactor system (see 2.10.2, working362
volume: 250 ml) for verification experiments. The formerly determined feeding363
strategy was slightly adapted due to practical bioreactor handling and to ensure364
process robustness. Therefore, the glucose concentration in the feed was previously365
identified to have only a low impact on the bioprocess (Möller et al., 2019b) and366
was changed to 111 mmol l−1 to avoid overfeeding. The glutamine concentration in367
the feed was 9 mmol l−1 and the feeding rate slightly resembled an exponential-like368
feeding (see 2.10.2).369
3.2.1 MC-based uncertainty quantification370
Three test runs were performed with the transferred and scaled up process strategy371
(stirred bioreactors, 250 ml) and the model parameters were estimated using the MC-372
based method (2.2). The experimental data and the model simulations including373
the parametric uncertainty-based prediction bands are shown in Figure 3.374
[Figure 3 about here.]375
The exponential growth phase was simulated well for the viable (see Fig. 3 A) and376
total cell density (Fig. 3 B) starting with approx. 0.3 · 106 cells ml−1 until a final377
concentration of 23 · 106 cells ml−1 (168 h). In general, further cell growth in the378
stationary phase progressed with reduced cell volume, limitations, and inhibitory379
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effects (Zeng et al., 1998). This was only partly included in the model and the380
maximal cell concentrations (Xv, Xt) were therefore slightly underestimated in the381
stationary phase. The glucose concentration (Fig. 3 C) was well predicted by the382
model including the feed pulses and the late glucose consumption after the last feed383
pulse (t > 138 h). The lactate concentration (Fig. 3 D) was predicted with vari-384
ations during lactate formation but the uptake of lactate was predicted sufficiently.385
Glutamine (Fig. 3 E) and ammonium (Fig. 3 F) were simulated accordingly with the386
experimental data and the antibody concentration (Fig. 3 G) increased constantly387
up to 387 ± 16 mg l−1 (average of 216 h and 240 h), which was also simulated.388
The volume (Fig. 3 H) was simulated as measured. R2 and NRMSD are shown in389
Supplementary Table 4. Overall, the simulations are in good agreement with the390
experimental data and the model reflects the bioprocess dynamics sufficiently. A391
description of the mechanistic links using a mathematical process model is the basis392
of the proposed concept and an appropriate description of the bioprocess needs to393
be ensured if the workflow is applied to a different cell line or process.394
3.2.2 Statistical comparison of parameter distributions395
As proposed in the parametric uncertainty-based workflow (Fig. 1, box 3), the396
means of the parameter distributions are statistically compared to evaluate if the397
dynamics of the bioprocess changed (Figure 4). The mean parameter values are398
listed in Supplementary Table 3.399
[Figure 4 about here.]400
An increase of 23 % was determined in the mean of µmax,norm, which shows a401
higher cell growth in pH and pO2 controlled bioreactors. Moreover, the glutamine-402
dependent model parameters differ significantly between both scales thus indicat-403
ing an average lower maximal uptake rate (qGln,max,norm) and a different affinity to404
the glutamine availability (kGln,norm, Ks,Gln,norm). The same trend was identified for405
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YAmm,Gln,norm with a higher ammonium formation in the bioreactor experiments com-406
pared to the shake flask cultivations. The dissociation of NH3 to NH4 is affected by407
the pH, thus explaining different ammonium concentrations in the controlled biore-408
actor experiments compared to the shake flask cultures (Lüdemann et al., 1994).409
qAb,norm was widely distributed in the shake flask cultivation, which indicates its410
correlation to the different investigated feeding strategies. The width of the whiskers411
was narrower in the bioreactor runs and the mean qAb,norm was reduced in the trans-412
ferred process. However, the overall process titer was comparable in both scales due413
to a higher viable cell density in the bioreactor cultivations. The means of kAmm,norm414
were not significantly different between both scales.415
In summary, differences in the dynamics of the growth and metabolism could be416
statistically identified for the transfer from process development (shake flask) to417
process implementation scale (stirred bioreactor). Moreover, these differences could418
be quantified and actions could be recommended based on the proposed workflow.419
Therefore, a re-validation of the formerly determined process strategy was recom-420
mended to ensure that the targeted design space (i.e. process strategy) is still met421
(Fig. 1, box 4).422
3.3 Validation of process strategy423
The validation of the formerly determined process strategy during process imple-424
mentation was performed using mDoE (Möller et al., 2019b). Therefore, the glu-425
tamine concentration in the feed (FGln,feed) and the relative feeding rate (FRate ·F =426
FRate,experimental) were defined as experimental factors. As an example, if F is de-427
fined as two, it means that all feed pulses (FRate,experimental, see 2.10.2) were doubled.428
Validation cultivations were planned using an I-optimal DoE design mode (16 rec-429
ommended experiments). The planned cultivations were simulated using the model430
(mean model parameters as in 3.2.2) and the maximal antibody concentration was431
defined as response. A quadratic response surface model (RSM) was estimated432
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(Design Expert 11) and the contour plot is seen in Figure 5 A.433
[Figure 5 about here.]434
The current process settings (Fig. 5 A) were at the maximal achievable antibody435
concentrations within a flat area, which reflects a stable point of operation. To vali-436
date the process strategy and to ensure process stability, four validation experiments437
were planned (white stars Fig. 5 A). It was aimed to ensure the stability of the pro-438
cess and to identify the shape of the maximum. The validation cultivations were439
experimentally performed and the experimental settings were included with their re-440
spective maximum antibody concentrations as design points in the DoE (Fig. 5 B).441
The shape of the maximal antibody concentration slightly changed with an optimal442
area between the performed validation cultivations, without harsh boundaries, and a443
flat area. The process stability could, therefore, be ensured and the formerly defined444
process (Fig. 5 A/B) was not changed. The main advantage of using mDoE here is445
that the stability of the process could be validated for the quantified changes in the446
process dynamics throughout the model parameter uncertainty determination.447
3.4 Scale-up from 250 ml to 2 l448
The implemented and validated process strategy was scaled up to 2 l scale, with449
the same hydrodynamics as at the 250 ml scale (see 2.10.3). Three test runs were450
performed and the scale-up was evaluated as proposed in the workflow (Fig. 1).451
Therefore, the model parameter distributions of the 2 l bioreactor experiments were452
estimated using the MC-based method (2.2) and statistically compared to the 250 ml453
scale.454
3.4.1 MC-based uncertainty quantification455
The model-based simulations, with 10% and 90% quantiles of simulation and the456
experimental data, are shown in Figure 6.457
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[Figure 6 about here.]458
Overall, the model predictions of the process at the 2 l (Fig. 6) scale were comparable459
to the process implementation at 250 ml scale (Fig. 3). Differences in R2 and460
NRMSD (see Supplementary Table 5) were low.461
3.4.2 Statistical comparison of parameter distributions462
The dynamics of the process were quantified with the statistical comparison of the463
parameter distributions (Figure 7). The means of the parameter distributions are464
shown in Supplementary Table 2.465
[Figure 7 about here.]466
µmax,norm, kGln,norm, Ks,Gln,norm, YAmm,Gln,norm, qGln,max,norm, and qAb,norm were iden-467
tified to be not significantly different on a 5% significance level. kAmm,norm was468
slightly higher in the scaled up process than during the process implementation469
runs (250 ml), but no differences were present in the maximal ammonium concen-470
tration and this change was therefore neglected. In summary, the process dynamics471
remain stable during the scale-up from process implementation to process scale-up.472
In conventional scale-up studies, the pure cultivation data of both scales (250 ml and473
2 l, respectively) would have been compared and a heuristic decision of the goodness474
of scale-up would have been drawn (e.g. same maximal titer, trends) (Rameez et al.,475
2014; Li et al., 2013). In the proposed workflow, the model uncertainty is quantified476
based on the available experimental variability and measurement error. Therefore,477
the process variability is determined on a timely axis (10% and 90% quantiles of478
simulation, Fig. 6) and in the parameter distributions (Fig. 7). This enables a479
knowledge-driven decision-making routine based on the process dynamics with the480
incorporation of the available data in the process model. In accordance with the481
proposed workflow (Fig. 1, 3) scale-up has proceeded with the confirmed process482
strategy.483
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3.5 Scale-up to 50 l pilot scale484
The process strategy was further scaled up to 50 l pilot scale and one verification485
cultivation was performed. In general, the quantification of the model parameter486
distributions requires multiple cultivation runs (i.e. 3), which were not available for487
the pilot scale. Therefore, the formerly determined parameter distributions (250 ml488
and 2 l, respectively) were used to predict the model parametric uncertainties of the489
pilot scale run a priori, as shown in Figure 8.490
[Figure 8 about here.]491
The experimental data is simulated well and is in good alignment with the mean492
and the 10% and 90% quantiles of simulation. The antibody concentration (Fig.493
8 G) increased constantly up to 367 mg l−1 and is comparable to the formerly494
scaled up processes. The main advantage of predicting the 10% and 90% quantiles495
based on the formerly determined parameter distributions is that the experimental496
variability is incorporated, even if the knowledge is gained at different scales. In497
summary, the process strategy was successfully scaled up to 50 l pilot scale and the498
formerly obtained knowledge was considered with the prediction of the 10% and499
90% quantiles.500
4 Conclusion501
A workflow for a knowledge-driven computational evaluation of the process strategy502
during scale-up was introduced. Therefore, the process dynamics are described by503
a mathematical process model and the model parameters are represented as prob-504
ability functions, which are determined based on the experimental variability. The505
probability functions derived at different scales are then statistically compared to506
identify changes in the bioprocess dynamics and validation of the process strat-507
egy is recommended if the dynamics are significantly different. Otherwise, scale-up508
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can proceed, and the process strategy is to be considered sufficient. This workflow509
was discussed on the scale-up of a CHO DP-12 fed-batch process, which was suc-510
cessfully scaled up to 50 l pilot scale. The introduced approach provides a novel,511
knowledge-driven decision-making tool for bioprocess development and implemen-512
tation. Further studies will focus on the automated re-design of process strategies513
with the consideration of the process model during scale-up and the combination of514
computational fluid dynamics with the process model.515
5 Nomenclature516
Variable Explanation Unit
ci concentration of the component i [mmol l
−1]
dj,max maximum value of a data set [-]
d difference in means [-]
F volume factor for feeding rate [-]
FGln,feed glutamine concentration in feed [mmol l
−1]
FRate feed rate [ml d
−1]
FRate,experimental implemented feed rate [ml d
−1]
ki growth constant [-]
Ki kinetic constant [mmol l
−1]
kLa volumetric mass transfer coefficient [s
−1]
P/VL volumetric power input [W m
−3]
qi production/consumption rate [mmol cell
−1 h−1]
R2 coefficient of determination [-]
S sensitivity coefficient [-]
t time [h]
V reactor working volume [l]
Xd dead cell density [cells ml
−1]
Xt total cell density [cells ml−1]
Xv viable cell density [cells ml−1]
yj state variables [-]
Yi yield coefficients [-]
ysim,j simulation of state variables [-]
µmax maximum specific growth rate [h−1]
σ2 variance [-]
|θ(k)| mean parameter [-]
θ(k) parameter [-]
517
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6 Abbreviations518
Abbreviation Explanation
Ab antibody
Amm ammonium
BR bioreactor
CI confidence interval
CFD computational fluid dynamics
CHO chinese hamster ovary
DAPI 4’,6-diamidin-2-phenylindol
Glc glucose
Gln glutamine
Lac lactate
MC Monte Carlo
mDoE model-assisted Design of Experiments
NRMSD normalized root mean square deviation
QbD quality by design
RAD relative average deviation
RSM response surface model
SF shake flask
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Up, pages 173–259. Springer Berlin Heidelberg, Berlin, Heidelberg. https://doi.org/10.1007/978-551
3-540-68182-3 5.552
Gmeiner, C., Saadati, A., Maresch, D., Stanimira, K., Frank, M., Altmann, F., Herwig,553
C., and Spadiut, O. (2015). Development of a fed-batch process for a recombinant554
pichia pastoris och1 strain expressing a plant peroxidase. Microbial cell factories, 14:1.555
https://doi.org/10.1186/s12934-014-0183-3.556
Guideline, I. H. T. et al. (2009). Pharmaceutical development. Q8 (2R). As revised in August.557
Herwig, C., Garcia-Aponte, O. F., Golabgir, A., and Rathore, A. S. (2015). Knowledge management558
in the qbd paradigm: manufacturing of biotech therapeutics. Trends in Biotechnology, 33(7):381559
– 387. https://doi.org/10.1016/j.tibtech.2015.04.004.560
Ivarsson, M., Noh, H., Morbidelli, M., and Soos, M. (2015). Insights into ph-561
induced metabolic switch by flux balance analysis. Biotechnology Progress, 31(2):347–357.562
https://doi.org/10.1002/btpr.2043.563
24
-
Ju, L.-K. and Chase, G. (1992). Improved scale-up strategies of bioreactors. Bioprocess Engineer-564
ing, 8(1-2):49–53.565
Kaiser, S. C., Eibl, R., and Eibl, D. (2011). Engineering characteristics of a single-use stirred566
bioreactor at bench-scale: The mobius cellready 3l bioreactor as a case study. Engineering in567
Life Sciences, 11(4):359–368. https://doi.org/10.1002/elsc.201000171.568
Kaiser, S. C., Kraume, M., Eibl, D., and Eibl, R. (2015). Single-use bioreactors for animal and569
human cells. In Animal Cell Culture, pages 445–500. Springer.570
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Figure 1: Proposed uncertainty-based workflow for the evaluation of scale-up
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Figure 2: Comparison of experimental (Exp:) and mean simulated data (Sim:) summa-
rized for 29 performed fed-batch cultivations in shake flasks (30 ml - 50 ml) (see 2.10.1).
R2 reflects goodness of fit against the optimal simulation (x=y); *= R2 for the first 144 h
(lactate formation); **= R2 for the first 96 h
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Figure 3: Experimental results (diamonds) of the fed-batch culture at 250 ml bioreactor
scale (2.10.2), solid line is the mean of 1000 simulations based on the MC-based method
(see 2.2), dashed line represents the 10% and 90% quantiles of the simulations based on
1000 independent parameter estimations; feeding was performed every 24 h (pointed line)
with a start at 48 h.
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Figure 4: Box-plots of the normalized parameters of the process development runs com-
pared to the process validation, box-plots show the intrinsic distribution of 1000 inde-
pendent parameter estimations per box, normalization of parameters on their individ-
ual starting parameter values during parameter estimation (see Supplementary Table 2),
*=significant, n. sig. = not significant
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Figure 5: Validation of feeding strategy with mDoE; A: contour plot with recommended
experiments (white stars); B: contour plot including performed validation experiments;
*= experimental data not considered in mDoE
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Figure 6: Experimental results (diamonds) of the fed-batch culture at 2 l bioreactor
scale, solid line is the median of 1000 simulations based on the MC-based method (see
2.2), dashed line represents the 10% and 90% quantiles of the simulations based on 1000
independent parameter estimations; feeding was performed every 24 h (pointed line) with
a start at 48 h.
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Figure 7: Box-plots of the normalized parameters of the process implementation runs
(250 ml) compared to the process scale-up (2 l), box-plots show the intrinsic distribution
of 1000 independent parameter estimations per box, normalization of parameters on their
individual starting parameter values during parameter estimation (Supplementary Table
2), *=significant, n. sig. = not significant
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Figure 8: Experimental results (diamonds) of the fed-batch culture at 50 l pilot scale,
solid line is the mean of 2000 simulations with the parameters previously estimated based
on the proposed MC method (see 2.2) for the process implementation (250 ml bioreactor)
and Scale-up (I) (2 l bioreactor) experiments, dashed line represents the 10% and 90%
quantiles of the simulations based on 2000 independent parameter estimations; feeding
was performed every 24 h (pointed line) with a start at 48 h.
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Table 1: Summarized performed experiments in this study
Aim Number of cultivations Working volume (cultivation system)
Process development 29 (2 blocks) 30 ml - 50 ml (shake flask, Corning, Netherlands)
Process implementation 3 250 ml (Ambr250, Sartorius Stedim Biotech, Germany)
Validation of process strategy 4 250 ml (Ambr 250)
Scale-up 3 2 l (UniVessel, Sartorius Stedim Biotech)
Scale-up 1 50 l (BIOSTAT STR50, Sartorius Stedim Biotech)
39
Table 2: Sensitive model parameters, sensitivity analysis as described in 2.7, *con-
sidered significant due to direct linkage to product titer
Parameter S [%]
µmax 103 %
kGln 51 %
kAmm 27 %
Ks,Gln 12 %
YAmm,Gln 45 %
qGln,max 44 %
q∗Ab significant
40
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1 Supplementary Material
1.1 Materials and Methods
1.1.1 Mathematical process model
Supplementary Table 1: Mathematical process model in batch mode, modified from [1, 2],
adapted from [3]
Balance equation Kinetic links
Biomass
dXv
dt
= (µ− µd) ·Xv (1) µ = µmax ·
cGlc
cGlc+Ks,Glc
· cGln
cGln+Ks,Gln
· KAmm
cAmm+KAmm
(10)
dXd
dt
= (µd) ·Xv (2)
dXt
dt
= µ ·Xv −KLys · (Xt −Xv) (3) µd = µd,min + µd,max ·
Ks,Glc
cGlc+Ks,Glc
·
Ks,Gln
cGln+Ks,Gln
· cAmm
cAmm+Ks,Amm
(11)
dVi
dt
=
dXv
dt
·Xt−
dXt
dt
·Xv
X2t
(4)
Substrates and metabolites
dcGlc
dt
= -qGlc ·Xv (5) qGlc = qGlc,max ·
cGlc
cGlc+kGlc
· ( µ
µ+µmax
+ 0.5) (12)
dcGln
dt
= -qGln ·Xv (6) qGln = qGln,max ·
cGln
cGln+kGln
(13)
dcLac
dt
= qLac ·Xv (7) qLac = YLac,Glc ·
cGlc
cLac
· qGlc − qLac,uptake (14)
cGlc < 0.5mmol · l−1 : qLac,uptake = qLac,uptake,max (15)
dcAmm
dt
= qAmm ·Xv (8) qAmm = YAmm,Gln · qGln (16)
Antibody
dcAb
dt
= qAb ·Xv (9) qAb = α (17)
cAmm ≥ KAmm :
dcAb
dt
= 0 (18)
1.1.2 Monte Carlo-based uncertainty quantification
3
Supplementary Table 2: Starting values, nomenclature as in main article
Symbol Unit Starting values
µd,min h
−1 0.001
µd,max h
−1 0.06
µmax h
−1 0.043
kGlc mmol · l−1 0.2
kGln mmol · l−1 2.5
kAmm mmol · l−1 10
kLys h
−1 0.001
Ks,Amm mmol · l−1 10
Ks,Glc mmol · l−1 0.02
Ks,Gln mmol · l−1 0.03
YAmm/Gln - 0.9
YLac/Glc - 0.25
qGlc,max 10
−9 ·mmol · cell−1 · h−1 0.05
qGln,max 10
−9 ·mmol · cell−1 · h−1 0.054
qLac,uptake,max 10
−9 ·mmol · cell−1 · h−1 0.2
qAb 10
−10 ·mg · cell−1 · h−1 3.12
1.2 Results and Discussion
1.2.1 Process development (30 ml - 50 ml): Identification of fed-batch strat-
egy
Supplementary Figure 1: Model parameter distribution, n=1000
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Supplementary Figure 3: Model parameter distribution, n=1000
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Supplementary Figure 4: Model parameter distribution, n=1000
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Supplementary Figure 5: Model parameter distribution, n=1000
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Supplementary Figure 6: Model parameter distribution, n=1000
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Supplementary Figure 7: Model parameter distribution, n=1000
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Supplementary Figure 8: Model parameter distribution, n=1000
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Supplementary Figure 9: Model parameter distribution, n=1000
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Supplementary Figure 10: Model parameter distribution, n=1000
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Supplementary Figure 11: Model parameter distribution, n=1000
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Supplementary Figure 12: Model parameter distribution, n=1000
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Supplementary Figure 13: Model parameter distribution, n=1000
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Supplementary Figure 14: Model parameter distribution, n=1000
18
70 
60 
50 ro -ro ,::, 
40 
0.. 
E 
ro 
30 ,_ 
::, 
Cl. 
::i:t: 
20 
10 
0 -d 
1 1.5 2 
... 
'" 
2.5 3 
rn rfhhn-m -
3.5 4 4.5 5 5.5 
X 10-1Q 
Supplementary Figure 15: Model parameter distribution, n=1000
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Supplementary Figure 16: Model parameter distribution, n=1000
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1.3 Estimation of model parameters
Supplementary Table 3: Adapted parameters at the investigated different scales, nomenclature
as in main article
Symbol Unit Development (3.1.1) Implementation (3.2.1) Scale-up (3.4.1)
µd,min h
−1 0.001 - -
µd,max h
−1 0.062 - -
µmax h
−1 0.037 0.048 0.048
kGlc mmol · l−1 0.20 - -
kGln mmol · l−1 2.31 2.76 2.6
kAmm mmol · l−1 11.67 11.62 12.6
kLys h
−1 0.001 - -
Ks,Amm mmol · l−1 10.23 - -
Ks,Glc mmol · l−1 0.02 - -
Ks,Gln mmol · l−1 0.03 0.29 0.03
YAmm/Gln - 0.79 0.91 0.97
YLac/Glc - 0.25 - -
qGlc,max 10
−9 ·mmol · cell−1 · h−1 0.05 - -
qGln,max 10
−9 ·mmol · cell−1 · h−1 0.05 0.05 0.05
qLac,uptake,max 10
−9 ·mmol · cell−1 · h−1 2.04 - -
qAb 10
−10 ·mg · cell−1 · h−1 2.59 1.99 1.98
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1.3.1 Sensitivity analysis
Supplementary Figure 17: Model uncertainty plots as described in materials and methods in
main manuscript
Supplementary Figure 18: Model uncertainty plots as described in materials and methods in
main manuscript
1.3.2 Results
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Supplementary Figure 19: Model uncertainty plots as described in materials and methods in
main manuscript
Supplementary Figure 20: Model uncertainty plots as described in materials and methods in
main manuscript
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Supplementary Table 4: R2 and NRMSD, process implementation (250 ml)
Concentration R2 NRMSD
Xv 0.90 0.09
Xt 0.93 0.08
cGlc 0.83 0.14
cLac 0.00 0.38
cGln 0.55 0.20
cAmm 0.63 0.15
cAb 0.94 0.08
V 0.92 0.12
Supplementary Table 5: R2 and NRMSD, Scale-up from 250 ml to 2 l
Concentration R2 NRMSD
Xv 0.91 0.08
Xt 0.94 0.08
cGlc 0.93 0.08
cLac 0.49 0.20
cGln 0.52 0.26
cAmm 0.58 0.15
cAb 0.94 0.07
V 0.92 0.12
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